nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—EPHA7—cerebellum—meningioma	0.00652	0.0165	CbGeAlD
Crizotinib—ROS1—brain—meningioma	0.00579	0.0146	CbGeAlD
Crizotinib—MET—brainstem—meningioma	0.00544	0.0138	CbGeAlD
Crizotinib—EPHA7—brain—meningioma	0.0053	0.0134	CbGeAlD
Crizotinib—IKBKE—cerebellum—meningioma	0.00494	0.0125	CbGeAlD
Crizotinib—PRKD1—medulla oblongata—meningioma	0.00457	0.0115	CbGeAlD
Crizotinib—TYRO3—brainstem—meningioma	0.00445	0.0113	CbGeAlD
Crizotinib—IGF1R—brainstem—meningioma	0.00428	0.0108	CbGeAlD
Crizotinib—MAP3K12—brainstem—meningioma	0.00379	0.00958	CbGeAlD
Crizotinib—STK35—brainstem—meningioma	0.00371	0.00938	CbGeAlD
Crizotinib—DCLK1—medulla oblongata—meningioma	0.00333	0.00841	CbGeAlD
Crizotinib—EPHA4—brainstem—meningioma	0.00331	0.00836	CbGeAlD
Crizotinib—PRKD1—cerebellum—meningioma	0.00323	0.00816	CbGeAlD
Crizotinib—LIMK1—cerebellum—meningioma	0.00318	0.00805	CbGeAlD
Crizotinib—FER—medulla oblongata—meningioma	0.00311	0.00785	CbGeAlD
Crizotinib—EPHA5—medulla oblongata—meningioma	0.00311	0.00785	CbGeAlD
Crizotinib—ALK—medulla oblongata—meningioma	0.00311	0.00785	CbGeAlD
Crizotinib—PRKD3—cerebellum—meningioma	0.0031	0.00785	CbGeAlD
Crizotinib—DSTYK—cerebellum—meningioma	0.00303	0.00766	CbGeAlD
Crizotinib—DCLK1—spinal cord—meningioma	0.00297	0.0075	CbGeAlD
Crizotinib—CASK—cerebellum—meningioma	0.00296	0.00749	CbGeAlD
Crizotinib—MAP4K2—medulla oblongata—meningioma	0.00294	0.00744	CbGeAlD
Crizotinib—NEK9—brain—meningioma	0.00288	0.00728	CbGeAlD
Crizotinib—MAPK7—cerebellum—meningioma	0.00287	0.00725	CbGeAlD
Crizotinib—EPHA8—cerebellum—meningioma	0.00284	0.00718	CbGeAlD
Crizotinib—TESK1—medulla oblongata—meningioma	0.0028	0.00709	CbGeAlD
Crizotinib—FER—spinal cord—meningioma	0.00277	0.007	CbGeAlD
Crizotinib—TYRO3—spinal cord—meningioma	0.00277	0.007	CbGeAlD
Crizotinib—EPHA5—spinal cord—meningioma	0.00277	0.007	CbGeAlD
Crizotinib—MET—cerebellum—meningioma	0.00268	0.00679	CbGeAlD
Crizotinib—MAP3K12—medulla oblongata—meningioma	0.00264	0.00668	CbGeAlD
Crizotinib—ACVR1—medulla oblongata—meningioma	0.00264	0.00668	CbGeAlD
Crizotinib—PRKD1—brain—meningioma	0.00262	0.00663	CbGeAlD
Crizotinib—CDK7—cerebellum—meningioma	0.0026	0.00657	CbGeAlD
Crizotinib—SIK2—brain—meningioma	0.00259	0.00654	CbGeAlD
Crizotinib—LIMK1—brain—meningioma	0.00259	0.00654	CbGeAlD
Crizotinib—TAOK2—cerebellum—meningioma	0.00258	0.00651	CbGeAlD
Crizotinib—TAOK3—brainstem—meningioma	0.00252	0.00638	CbGeAlD
Crizotinib—PRKD3—brain—meningioma	0.00252	0.00638	CbGeAlD
Crizotinib—TESK1—spinal cord—meningioma	0.0025	0.00633	CbGeAlD
Crizotinib—ACVR1B—cerebellum—meningioma	0.00248	0.00627	CbGeAlD
Crizotinib—DSTYK—brain—meningioma	0.00246	0.00622	CbGeAlD
Crizotinib—LTK—brain—meningioma	0.0024	0.00608	CbGeAlD
Crizotinib—CASK—brain—meningioma	0.0024	0.00608	CbGeAlD
Crizotinib—RIPK2—medulla oblongata—meningioma	0.00238	0.00603	CbGeAlD
Crizotinib—LIMK2—spinal cord—meningioma	0.00238	0.00602	CbGeAlD
Crizotinib—JAK3—cerebellum—meningioma	0.00237	0.00599	CbGeAlD
Crizotinib—MAP3K12—spinal cord—meningioma	0.00235	0.00595	CbGeAlD
Crizotinib—ACVR1—spinal cord—meningioma	0.00235	0.00595	CbGeAlD
Crizotinib—DCLK1—cerebellum—meningioma	0.00235	0.00595	CbGeAlD
Crizotinib—MAPK7—brain—meningioma	0.00233	0.00589	CbGeAlD
Crizotinib—STK4—cerebellum—meningioma	0.00232	0.00588	CbGeAlD
Crizotinib—EPHA4—medulla oblongata—meningioma	0.00231	0.00583	CbGeAlD
Crizotinib—EPHA8—brain—meningioma	0.00231	0.00583	CbGeAlD
Crizotinib—FES—brain—meningioma	0.00231	0.00583	CbGeAlD
Crizotinib—BMP2K—spinal cord—meningioma	0.00222	0.00562	CbGeAlD
Crizotinib—TBK1—medulla oblongata—meningioma	0.00221	0.0056	CbGeAlD
Crizotinib—TYK2—medulla oblongata—meningioma	0.0022	0.00556	CbGeAlD
Crizotinib—TYRO3—cerebellum—meningioma	0.0022	0.00555	CbGeAlD
Crizotinib—FER—cerebellum—meningioma	0.0022	0.00555	CbGeAlD
Crizotinib—EPHA5—cerebellum—meningioma	0.0022	0.00555	CbGeAlD
Crizotinib—MET—brain—meningioma	0.00218	0.00551	CbGeAlD
Crizotinib—TNK1—cerebellum—meningioma	0.00217	0.0055	CbGeAlD
Crizotinib—BMPR1B—cerebellum—meningioma	0.00215	0.00544	CbGeAlD
Crizotinib—RPS6KB1—medulla oblongata—meningioma	0.00213	0.00539	CbGeAlD
Crizotinib—RIPK2—spinal cord—meningioma	0.00213	0.00538	CbGeAlD
Crizotinib—TNK2—cerebellum—meningioma	0.00211	0.00534	CbGeAlD
Crizotinib—IGF1R—cerebellum—meningioma	0.00211	0.00534	CbGeAlD
Crizotinib—AXL—medulla oblongata—meningioma	0.00211	0.00533	CbGeAlD
Crizotinib—CDK7—brain—meningioma	0.00211	0.00533	CbGeAlD
Crizotinib—TAOK2—brain—meningioma	0.00209	0.00529	CbGeAlD
Crizotinib—MAP4K2—cerebellum—meningioma	0.00208	0.00526	CbGeAlD
Crizotinib—TIE1—cerebellum—meningioma	0.00205	0.00519	CbGeAlD
Crizotinib—STK3—cerebellum—meningioma	0.00205	0.00519	CbGeAlD
Crizotinib—SLK—medulla oblongata—meningioma	0.00203	0.00513	CbGeAlD
Crizotinib—EPHB4—medulla oblongata—meningioma	0.00202	0.0051	CbGeAlD
Crizotinib—ACVR1B—brain—meningioma	0.00202	0.0051	CbGeAlD
Crizotinib—EPHA3—brain—meningioma	0.00202	0.0051	CbGeAlD
Crizotinib—JAK2—medulla oblongata—meningioma	0.002	0.00506	CbGeAlD
Crizotinib—TESK1—cerebellum—meningioma	0.00198	0.00502	CbGeAlD
Crizotinib—PTK2—spinal cord—meningioma	0.00197	0.00499	CbGeAlD
Crizotinib—TBK1—spinal cord—meningioma	0.00197	0.00499	CbGeAlD
Crizotinib—TYK2—spinal cord—meningioma	0.00196	0.00496	CbGeAlD
Crizotinib—MERTK—cerebellum—meningioma	0.00193	0.00488	CbGeAlD
Crizotinib—MAP4K5—medulla oblongata—meningioma	0.00193	0.00488	CbGeAlD
Crizotinib—TEK—medulla oblongata—meningioma	0.00193	0.00488	CbGeAlD
Crizotinib—MAP3K3—medulla oblongata—meningioma	0.00193	0.00488	CbGeAlD
Crizotinib—EPHA6—brain—meningioma	0.00192	0.00486	CbGeAlD
Crizotinib—JAK3—brain—meningioma	0.00192	0.00486	CbGeAlD
Crizotinib—DCLK1—brain—meningioma	0.00191	0.00483	CbGeAlD
Crizotinib—RPS6KB1—spinal cord—meningioma	0.0019	0.0048	CbGeAlD
Crizotinib—PLK4—brain—meningioma	0.0019	0.0048	CbGeAlD
Crizotinib—STK4—brain—meningioma	0.00189	0.00477	CbGeAlD
Crizotinib—LIMK2—cerebellum—meningioma	0.00189	0.00477	CbGeAlD
Crizotinib—AXL—spinal cord—meningioma	0.00188	0.00476	CbGeAlD
Crizotinib—NUAK2—cerebellum—meningioma	0.00188	0.00476	CbGeAlD
Crizotinib—FLT3—cerebellum—meningioma	0.00187	0.00472	CbGeAlD
Crizotinib—ACVR1—cerebellum—meningioma	0.00187	0.00472	CbGeAlD
Crizotinib—MAP3K12—cerebellum—meningioma	0.00187	0.00472	CbGeAlD
Crizotinib—EPHB6—medulla oblongata—meningioma	0.00184	0.00466	CbGeAlD
Crizotinib—STK35—cerebellum—meningioma	0.00183	0.00463	CbGeAlD
Crizotinib—SLK—spinal cord—meningioma	0.00181	0.00458	CbGeAlD
Crizotinib—EPHB4—spinal cord—meningioma	0.0018	0.00454	CbGeAlD
Crizotinib—JAK2—spinal cord—meningioma	0.00178	0.00451	CbGeAlD
Crizotinib—ALK—brain—meningioma	0.00178	0.00451	CbGeAlD
Crizotinib—TYRO3—brain—meningioma	0.00178	0.00451	CbGeAlD
Crizotinib—FER—brain—meningioma	0.00178	0.00451	CbGeAlD
Crizotinib—EPHA5—brain—meningioma	0.00178	0.00451	CbGeAlD
Crizotinib—ABL2—cerebellum—meningioma	0.00178	0.00451	CbGeAlD
Crizotinib—YES1—medulla oblongata—meningioma	0.00178	0.0045	CbGeAlD
Crizotinib—LYN—brain—meningioma	0.00177	0.00449	CbGeAlD
Crizotinib—TNK1—brain—meningioma	0.00176	0.00446	CbGeAlD
Crizotinib—BMP2K—cerebellum—meningioma	0.00176	0.00445	CbGeAlD
Crizotinib—TAOK3—medulla oblongata—meningioma	0.00176	0.00445	CbGeAlD
Crizotinib—MAP4K1—brain—meningioma	0.00175	0.00442	CbGeAlD
Crizotinib—BMPR1B—brain—meningioma	0.00175	0.00442	CbGeAlD
Crizotinib—MAP3K19—brain—meningioma	0.00175	0.00442	CbGeAlD
Crizotinib—ABL1—brainstem—meningioma	0.00174	0.00441	CbGeAlD
Crizotinib—MAP3K3—spinal cord—meningioma	0.00172	0.00435	CbGeAlD
Crizotinib—TEK—spinal cord—meningioma	0.00172	0.00435	CbGeAlD
Crizotinib—MAP4K5—spinal cord—meningioma	0.00172	0.00435	CbGeAlD
Crizotinib—IGF1R—brain—meningioma	0.00171	0.00433	CbGeAlD
Crizotinib—TNK2—brain—meningioma	0.00171	0.00433	CbGeAlD
Crizotinib—PTK2B—cerebellum—meningioma	0.0017	0.0043	CbGeAlD
Crizotinib—MAP4K2—brain—meningioma	0.00169	0.00427	CbGeAlD
Crizotinib—RIPK2—cerebellum—meningioma	0.00169	0.00427	CbGeAlD
Crizotinib—STK3—brain—meningioma	0.00167	0.00422	CbGeAlD
Crizotinib—TIE1—brain—meningioma	0.00167	0.00422	CbGeAlD
Crizotinib—EPHB6—spinal cord—meningioma	0.00164	0.00416	CbGeAlD
Crizotinib—EPHA4—cerebellum—meningioma	0.00163	0.00412	CbGeAlD
Crizotinib—AURKA—brain—meningioma	0.00162	0.00411	CbGeAlD
Crizotinib—TESK1—brain—meningioma	0.00161	0.00407	CbGeAlD
Crizotinib—MAP3K2—cerebellum—meningioma	0.0016	0.00404	CbGeAlD
Crizotinib—YES1—spinal cord—meningioma	0.00159	0.00402	CbGeAlD
Crizotinib—TAOK3—spinal cord—meningioma	0.00157	0.00397	CbGeAlD
Crizotinib—MERTK—brain—meningioma	0.00157	0.00396	CbGeAlD
Crizotinib—PTK2—cerebellum—meningioma	0.00157	0.00396	CbGeAlD
Crizotinib—TBK1—cerebellum—meningioma	0.00157	0.00396	CbGeAlD
Crizotinib—TYK2—cerebellum—meningioma	0.00156	0.00393	CbGeAlD
Crizotinib—CSF1R—medulla oblongata—meningioma	0.00154	0.00389	CbGeAlD
Crizotinib—IRAK1—cerebellum—meningioma	0.00153	0.00388	CbGeAlD
Crizotinib—LIMK2—brain—meningioma	0.00153	0.00388	CbGeAlD
Crizotinib—SRC—spinal cord—meningioma	0.00153	0.00386	CbGeAlD
Crizotinib—NUAK2—brain—meningioma	0.00153	0.00386	CbGeAlD
Crizotinib—MAP3K12—brain—meningioma	0.00152	0.00384	CbGeAlD
Crizotinib—ACVR1—brain—meningioma	0.00152	0.00384	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—meningioma	0.00151	0.00381	CbGeAlD
Crizotinib—AXL—cerebellum—meningioma	0.00149	0.00377	CbGeAlD
Crizotinib—STK35—brain—meningioma	0.00149	0.00376	CbGeAlD
Crizotinib—ABL2—brain—meningioma	0.00145	0.00366	CbGeAlD
Crizotinib—SLK—cerebellum—meningioma	0.00144	0.00363	CbGeAlD
Crizotinib—BMP2K—brain—meningioma	0.00143	0.00362	CbGeAlD
Crizotinib—EPHB4—cerebellum—meningioma	0.00142	0.0036	CbGeAlD
Crizotinib—JAK2—cerebellum—meningioma	0.00141	0.00358	CbGeAlD
Crizotinib—PTK2B—brain—meningioma	0.00138	0.00349	CbGeAlD
Crizotinib—CSF1R—spinal cord—meningioma	0.00137	0.00347	CbGeAlD
Crizotinib—RIPK2—brain—meningioma	0.00137	0.00346	CbGeAlD
Crizotinib—MAP4K5—cerebellum—meningioma	0.00136	0.00345	CbGeAlD
Crizotinib—MAP3K3—cerebellum—meningioma	0.00136	0.00345	CbGeAlD
Crizotinib—TEK—cerebellum—meningioma	0.00136	0.00345	CbGeAlD
Crizotinib—EPHA4—brain—meningioma	0.00132	0.00335	CbGeAlD
Crizotinib—EPHB6—cerebellum—meningioma	0.0013	0.0033	CbGeAlD
Crizotinib—MAP3K2—brain—meningioma	0.0013	0.00328	CbGeAlD
Crizotinib—PTK2—brain—meningioma	0.00127	0.00322	CbGeAlD
Crizotinib—TBK1—brain—meningioma	0.00127	0.00322	CbGeAlD
Crizotinib—TYK2—brain—meningioma	0.00126	0.00319	CbGeAlD
Crizotinib—YES1—cerebellum—meningioma	0.00126	0.00319	CbGeAlD
Crizotinib—STK10—cerebellum—meningioma	0.00125	0.00316	CbGeAlD
Crizotinib—IRAK1—brain—meningioma	0.00125	0.00315	CbGeAlD
Crizotinib—TAOK3—cerebellum—meningioma	0.00124	0.00314	CbGeAlD
Crizotinib—RPS6KB1—brain—meningioma	0.00122	0.00309	CbGeAlD
Crizotinib—ABL1—medulla oblongata—meningioma	0.00122	0.00308	CbGeAlD
Crizotinib—FGR—brain—meningioma	0.00122	0.00308	CbGeAlD
Crizotinib—SRC—cerebellum—meningioma	0.00121	0.00306	CbGeAlD
Crizotinib—AXL—brain—meningioma	0.00121	0.00306	CbGeAlD
Crizotinib—SLK—brain—meningioma	0.00117	0.00295	CbGeAlD
Crizotinib—EPHB4—brain—meningioma	0.00116	0.00293	CbGeAlD
Crizotinib—JAK2—brain—meningioma	0.00115	0.00291	CbGeAlD
Crizotinib—EPHA2—brain—meningioma	0.00114	0.00287	CbGeAlD
Crizotinib—MAP3K3—brain—meningioma	0.00111	0.0028	CbGeAlD
Crizotinib—TEK—brain—meningioma	0.00111	0.0028	CbGeAlD
Crizotinib—MAP4K5—brain—meningioma	0.00111	0.0028	CbGeAlD
Crizotinib—CSF1R—cerebellum—meningioma	0.00109	0.00275	CbGeAlD
Crizotinib—ABL1—spinal cord—meningioma	0.00108	0.00274	CbGeAlD
Crizotinib—EPHB6—brain—meningioma	0.00106	0.00268	CbGeAlD
Crizotinib—YES1—brain—meningioma	0.00102	0.00259	CbGeAlD
Crizotinib—STK10—brain—meningioma	0.00101	0.00256	CbGeAlD
Crizotinib—TAOK3—brain—meningioma	0.00101	0.00255	CbGeAlD
Crizotinib—SRC—brain—meningioma	0.000984	0.00249	CbGeAlD
Crizotinib—CSF1R—brain—meningioma	0.000883	0.00223	CbGeAlD
Crizotinib—ABL1—cerebellum—meningioma	0.00086	0.00217	CbGeAlD
Crizotinib—ABL1—brain—meningioma	0.000698	0.00177	CbGeAlD
Crizotinib—ABCB1—medulla oblongata—meningioma	0.000378	0.000956	CbGeAlD
Crizotinib—ABCB1—spinal cord—meningioma	0.000337	0.000853	CbGeAlD
Crizotinib—ABCB1—cerebellum—meningioma	0.000267	0.000676	CbGeAlD
Crizotinib—ABCB1—brain—meningioma	0.000217	0.000549	CbGeAlD
Crizotinib—FES—Signaling Pathways—PTEN—meningioma	6.89e-05	0.000114	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALAD—meningioma	6.77e-05	0.000112	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SMO—meningioma	6.76e-05	0.000112	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—ERBB2—meningioma	6.75e-05	0.000112	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PDGFB—meningioma	6.62e-05	0.00011	CbGpPWpGaD
Crizotinib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	6.62e-05	0.00011	CbGpPWpGaD
Crizotinib—SRC—Signaling by FGFR in disease—AKT1—meningioma	6.62e-05	0.000109	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR—AKT1—meningioma	6.56e-05	0.000108	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—AKT1—meningioma	6.54e-05	0.000108	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR in Cancer—AKT1—meningioma	6.5e-05	0.000108	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PGR—meningioma	6.49e-05	0.000107	CbGpPWpGaD
Crizotinib—SRC—Signaling by PDGF—AKT1—meningioma	6.47e-05	0.000107	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HES1—meningioma	6.44e-05	0.000107	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PDGFB—meningioma	6.42e-05	0.000106	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	6.39e-05	0.000106	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HES1—meningioma	6.35e-05	0.000105	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TP53—meningioma	6.34e-05	0.000105	CbGpPWpGaD
Crizotinib—JAK2—Disease—HES1—meningioma	6.33e-05	0.000105	CbGpPWpGaD
Crizotinib—LYN—Immune System—PDGFB—meningioma	6.27e-05	0.000104	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—AKT1—meningioma	6.26e-05	0.000104	CbGpPWpGaD
Crizotinib—LCK—Platelet activation, signaling and aggregation—AKT1—meningioma	6.26e-05	0.000104	CbGpPWpGaD
Crizotinib—SRC—Membrane Trafficking—AKT1—meningioma	6.25e-05	0.000103	CbGpPWpGaD
Crizotinib—SRC—Focal Adhesion—AKT1—meningioma	6.25e-05	0.000103	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TP53—meningioma	6.25e-05	0.000103	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—AKT1—meningioma	6.25e-05	0.000103	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PDGFB—meningioma	6.24e-05	0.000103	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—PTEN—meningioma	6.23e-05	0.000103	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	6.23e-05	0.000103	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—PTEN—meningioma	6.21e-05	0.000103	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TP53—meningioma	6.2e-05	0.000103	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TP53—meningioma	6.2e-05	0.000103	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TSHB—meningioma	6.17e-05	0.000102	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—PTEN—meningioma	6.15e-05	0.000102	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—AKT1—meningioma	6.14e-05	0.000102	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—PTEN—meningioma	6.12e-05	0.000101	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—PTEN—meningioma	6.12e-05	0.000101	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—PTEN—meningioma	6.1e-05	0.000101	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HES1—meningioma	6.03e-05	9.97e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—PTEN—meningioma	6.01e-05	9.94e-05	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—AKT1—meningioma	5.97e-05	9.88e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—PTEN—meningioma	5.97e-05	9.88e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—PTEN—meningioma	5.95e-05	9.84e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—AKT1—meningioma	5.95e-05	9.83e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—ERBB2—meningioma	5.93e-05	9.8e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SMO—meningioma	5.92e-05	9.8e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—ERBB2—meningioma	5.91e-05	9.78e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—PTEN—meningioma	5.91e-05	9.77e-05	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—AKT1—meningioma	5.9e-05	9.76e-05	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—AKT1—meningioma	5.89e-05	9.74e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TP53—meningioma	5.88e-05	9.72e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PDGFB—meningioma	5.87e-05	9.7e-05	CbGpPWpGaD
Crizotinib—SRC—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	5.86e-05	9.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HES1—meningioma	5.85e-05	9.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—AKT1—meningioma	5.82e-05	9.62e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TSHB—meningioma	5.78e-05	9.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—PTEN—meningioma	5.76e-05	9.52e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—ERBB2—meningioma	5.71e-05	9.45e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PGR—meningioma	5.68e-05	9.39e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—ERBB2—meningioma	5.68e-05	9.39e-05	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—AKT1—meningioma	5.67e-05	9.38e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—ERBB2—meningioma	5.63e-05	9.32e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HES1—meningioma	5.55e-05	9.17e-05	CbGpPWpGaD
Crizotinib—SRC—Platelet activation, signaling and aggregation—AKT1—meningioma	5.54e-05	9.17e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PDGFB—meningioma	5.51e-05	9.11e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—AKT1—meningioma	5.46e-05	9.03e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PDGFB—meningioma	5.43e-05	8.99e-05	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—AKT1—meningioma	5.43e-05	8.99e-05	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—AKT1—meningioma	5.43e-05	8.99e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PDGFB—meningioma	5.42e-05	8.96e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—AKT1—meningioma	5.38e-05	8.9e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TP53—meningioma	5.38e-05	8.89e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—AKT1—meningioma	5.35e-05	8.85e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—ERBB2—meningioma	5.34e-05	8.84e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—ERBB2—meningioma	5.28e-05	8.73e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—AKT1—meningioma	5.28e-05	8.73e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SMO—meningioma	5.24e-05	8.67e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—AKT1—meningioma	5.24e-05	8.66e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—AKT1—meningioma	5.24e-05	8.66e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—ERBB2—meningioma	5.23e-05	8.66e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—ERBB2—meningioma	5.19e-05	8.58e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PDGFB—meningioma	5.15e-05	8.52e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—PDGFB—meningioma	5.14e-05	8.5e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—AKT1—meningioma	5.09e-05	8.42e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—PTEN—meningioma	5.04e-05	8.34e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PGR—meningioma	5.03e-05	8.32e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—ERBB2—meningioma	5.03e-05	8.31e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PDGFB—meningioma	5e-05	8.28e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—AKT1—meningioma	4.96e-05	8.21e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—AKT1—meningioma	4.96e-05	8.2e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HES1—meningioma	4.91e-05	8.12e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—PTEN—meningioma	4.87e-05	8.06e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—PTEN—meningioma	4.84e-05	8.01e-05	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—AKT1—meningioma	4.84e-05	8e-05	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—AKT1—meningioma	4.82e-05	7.97e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—PTEN—meningioma	4.8e-05	7.95e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—ERBB2—meningioma	4.79e-05	7.92e-05	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—AKT1—meningioma	4.75e-05	7.86e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PDGFB—meningioma	4.74e-05	7.84e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HES1—meningioma	4.74e-05	7.84e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—ERBB2—meningioma	4.71e-05	7.78e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—meningioma	4.7e-05	7.77e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—meningioma	4.66e-05	7.71e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—meningioma	4.64e-05	7.67e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—ERBB2—meningioma	4.64e-05	7.67e-05	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—AKT1—meningioma	4.56e-05	7.55e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—PTEN—meningioma	4.56e-05	7.54e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—PDGFB—meningioma	4.55e-05	7.52e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—AKT1—meningioma	4.54e-05	7.51e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—AKT1—meningioma	4.51e-05	7.46e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—AKT1—meningioma	4.51e-05	7.46e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—PTEN—meningioma	4.5e-05	7.45e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—PTEN—meningioma	4.46e-05	7.38e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—ERBB2—meningioma	4.44e-05	7.34e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—AKT1—meningioma	4.44e-05	7.34e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HES1—meningioma	4.43e-05	7.33e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—PTEN—meningioma	4.42e-05	7.32e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—AKT1—meningioma	4.39e-05	7.27e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—AKT1—meningioma	4.38e-05	7.24e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TSHB—meningioma	4.36e-05	7.22e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	4.36e-05	7.22e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—meningioma	4.36e-05	7.22e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—ERBB2—meningioma	4.3e-05	7.12e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—PTEN—meningioma	4.29e-05	7.09e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—AKT1—meningioma	4.26e-05	7.04e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—meningioma	4.25e-05	7.03e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—ERBB2—meningioma	4.2e-05	6.95e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PDGFB—meningioma	4.2e-05	6.94e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—ERBB2—meningioma	4.18e-05	6.92e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALAD—meningioma	4.17e-05	6.9e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—meningioma	4.16e-05	6.88e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PTEN—meningioma	4.08e-05	6.75e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PDGFB—meningioma	4.05e-05	6.7e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—AKT1—meningioma	4.01e-05	6.64e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PTEN—meningioma	4.01e-05	6.64e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—AKT1—meningioma	4.01e-05	6.64e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—AKT1—meningioma	3.99e-05	6.61e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—AKT1—meningioma	3.97e-05	6.56e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PTEN—meningioma	3.96e-05	6.54e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—AKT1—meningioma	3.94e-05	6.51e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—ERBB2—meningioma	3.93e-05	6.5e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—AKT1—meningioma	3.92e-05	6.48e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HES1—meningioma	3.88e-05	6.42e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—meningioma	3.82e-05	6.32e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PDGFB—meningioma	3.79e-05	6.27e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PTEN—meningioma	3.79e-05	6.26e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—AKT1—meningioma	3.76e-05	6.21e-05	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—AKT1—meningioma	3.73e-05	6.17e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ERBB2—meningioma	3.69e-05	6.11e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	3.68e-05	6.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—AKT1—meningioma	3.68e-05	6.09e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PTEN—meningioma	3.67e-05	6.07e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ERBB2—meningioma	3.64e-05	6.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—ERBB2—meningioma	3.63e-05	6e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—AKT1—meningioma	3.59e-05	5.94e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—PTEN—meningioma	3.58e-05	5.92e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—AKT1—meningioma	3.58e-05	5.92e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PTEN—meningioma	3.57e-05	5.9e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—AKT1—meningioma	3.54e-05	5.86e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—AKT1—meningioma	3.53e-05	5.83e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—AKT1—meningioma	3.53e-05	5.83e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—AKT1—meningioma	3.51e-05	5.81e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—AKT1—meningioma	3.46e-05	5.73e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ERBB2—meningioma	3.45e-05	5.71e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ERBB2—meningioma	3.44e-05	5.69e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—AKT1—meningioma	3.44e-05	5.69e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HES1—meningioma	3.44e-05	5.69e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—AKT1—meningioma	3.43e-05	5.67e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—AKT1—meningioma	3.4e-05	5.63e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—meningioma	3.38e-05	5.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ERBB2—meningioma	3.35e-05	5.55e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PTEN—meningioma	3.35e-05	5.54e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PDGFB—meningioma	3.32e-05	5.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—AKT1—meningioma	3.32e-05	5.49e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—AKT1—meningioma	3.23e-05	5.34e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB2—meningioma	3.18e-05	5.26e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PTEN—meningioma	3.15e-05	5.21e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PTEN—meningioma	3.11e-05	5.14e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTEN—meningioma	3.09e-05	5.12e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—meningioma	3.07e-05	5.08e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB2—meningioma	3.05e-05	5.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PTEN—meningioma	2.95e-05	4.87e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PDGFB—meningioma	2.94e-05	4.86e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—PTEN—meningioma	2.94e-05	4.86e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—meningioma	2.91e-05	4.82e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—meningioma	2.91e-05	4.8e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTEN—meningioma	2.86e-05	4.73e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—meningioma	2.86e-05	4.72e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—meningioma	2.81e-05	4.65e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—meningioma	2.81e-05	4.64e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—meningioma	2.79e-05	4.61e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—meningioma	2.79e-05	4.61e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—meningioma	2.77e-05	4.58e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—meningioma	2.74e-05	4.53e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—meningioma	2.72e-05	4.49e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTEN—meningioma	2.71e-05	4.48e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—meningioma	2.7e-05	4.46e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TSHB—meningioma	2.69e-05	4.45e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—meningioma	2.63e-05	4.34e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—PTEN—meningioma	2.6e-05	4.3e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—meningioma	2.6e-05	4.29e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—meningioma	2.58e-05	4.27e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—meningioma	2.57e-05	4.25e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—meningioma	2.55e-05	4.22e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—meningioma	2.54e-05	4.2e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—meningioma	2.51e-05	4.14e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—meningioma	2.47e-05	4.08e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—meningioma	2.4e-05	3.97e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—meningioma	2.35e-05	3.89e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—meningioma	2.33e-05	3.85e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—meningioma	2.32e-05	3.83e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—meningioma	2.31e-05	3.83e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—meningioma	2.28e-05	3.77e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—meningioma	2.23e-05	3.68e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—meningioma	2.18e-05	3.61e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—meningioma	2.17e-05	3.58e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—meningioma	2.15e-05	3.55e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—meningioma	2.12e-05	3.51e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—meningioma	2.12e-05	3.5e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—meningioma	2.11e-05	3.5e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—meningioma	2.06e-05	3.41e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—meningioma	2.05e-05	3.4e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—meningioma	2.01e-05	3.33e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—meningioma	1.97e-05	3.26e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—meningioma	1.95e-05	3.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—meningioma	1.93e-05	3.2e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—meningioma	1.9e-05	3.14e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—meningioma	1.82e-05	3e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—meningioma	1.79e-05	2.96e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—meningioma	1.78e-05	2.95e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—meningioma	1.7e-05	2.81e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—meningioma	1.69e-05	2.8e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—meningioma	1.68e-05	2.78e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—meningioma	1.65e-05	2.73e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—meningioma	1.58e-05	2.61e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—meningioma	1.58e-05	2.61e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—meningioma	1.56e-05	2.58e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—meningioma	1.5e-05	2.48e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—meningioma	1.48e-05	2.45e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—meningioma	1.38e-05	2.29e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—meningioma	1.33e-05	2.21e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—meningioma	1.3e-05	2.14e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—meningioma	1.25e-05	2.07e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—meningioma	1.19e-05	1.97e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—meningioma	1.15e-05	1.9e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—meningioma	1.09e-05	1.81e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—meningioma	9.68e-06	1.6e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—meningioma	9.08e-06	1.5e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—meningioma	7.33e-06	1.21e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—meningioma	6.85e-06	1.13e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—meningioma	4.22e-06	6.98e-06	CbGpPWpGaD
